Weight loss in narcolepsy patients treated with sodium oxybate

Sleep Medicine

Volumn 10, Issue 6, 2009, Pages 661-663

  Husain, Aatif M ^a,b   Ristanovic, Ruzica K ^c   Bogan, Richard K ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c EVANSTON HOSPITAL   (United States)

^d SleepMed of South Carolina   (United States)

Author keywords

Hypocretin; Hypothalamus; Narcolepsy; Obesity; Sodium oxybate; Weight loss

Indexed keywords

OXYBATE SODIUM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NARCOLEPSY; PRIORITY JOURNAL; STUDENT T TEST; TREATMENT DURATION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; CATAPLEXY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; RETROSPECTIVE STUDIES; SODIUM OXYBATE; WEIGHT LOSS; YOUNG ADULT;

EID: 67349158754     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2008.05.012     Document Type: Article

References (28)

1. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50 (2001) 381-388
2. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
3. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95 (1998) 322-327
4. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
5. Dahmen N., Bierbrauer J., and Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 251 (2001) 85-89
6. Kok S.W., Overeem S., Visscher T.L., Lammers G.J., Seidell J.C., Pijl H., et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 11 (2003) 1147-1154
7. Schuld A., Hebebrand J., Geller F., and Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 355 (2000) 1274-1275
8. Anonymous. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-49.
9. Anonymous. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-421.
10. Anonymous. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-397.
11. Ristanovic R.K. Decreased body-mass index (BMI) in narcoleptic patients treated with sodium oxybate. Sleep 26 (2003) A87-A88
12. Lammers G.J., Pijl H., Iestra J., Langius J.A., Buunk G., and Meinders A.E. Spontaneous food choice in narcolepsy. Sleep 19 (1996) 75-76
13. Bernardis L.L., and Bellinger L.L. The lateral hypothalamic area revisited: ingestive behavior. Neurosci Biobehav Rev 20 (1996) 189-287
14. Steffens A.B. Influence of reversible obesity on eating behavior, blood glucose, and insulin in the rat. Am J Physiol 228 (1975) 1738-1744
15. Dube M.G., Kalra S.P., and Kalra P.S. Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res 842 (1999) 473-477
16. Beuckmann C.T., and Yanagisawa M. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med 80 (2002) 329-342
17. Crocker A., Espana R.A., Papadopoulou M., Saper C.B., Faraco J., Sakurai T., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65 (2005) 1184-1188
18. Kok S.W., Meinders A.E., Overeem S., Lammers G.J., Roelfsema F., Frolich M., et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 87 (2002) 805-809
19. Chou T.C., Lee C.E., Lu J., Elmquist J.K., Hara J., Willie J.T., et al. Orexin (hypocretin) neurons contain dynorphin. J Neurosci 21 (2001) RC168
20. Hara J., Yanagisawa M., and Sakurai T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 380 (2005) 239-242
21. Overeem S., Kok S.W., Lammers G.J., Vein A.A., Frolich M., Meinders A.E., et al. Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. Am J Physiol Endocrinol Metab 284 (2003) E641-647
22. Kok S.W., Roelfsema F., Overeem S., Lammers G.J., Frolich M., Meinders A.E., et al. Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab 288 (2005) E892-E899
23. Honda Y., Doi Y., Ninomiya R., and Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9 (1986) 254-259
24. Sachs C., and Kaijser L. Autonomic control of cardiovascular reflexes in narcolepsy. J Neurol Neurosurg Psychiatry 43 (1980) 535-539
25. B receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 287 (1998) 261-265
26. Thorpy M.J. Sodium oxybate for the treatment of narcolepsy. Expert Opin Pharmacother 6 (2005) 329-335
27. Dauvilliers Y., Baumann C.R., Carlander B., Bischof M., Blatter T., Lecendreux M., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74 (2003) 1667-1673
28. Krahn L.E., Pankratz V.S., Oliver L., Boeve B.F., and Silber M.H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 25 (2002) 733-736